Saeed Alsharif1,2, Karin Jonstam3,4, Thibaut van Zele1, Philippe Gevaert1, Gabriele Holtappels1, Claus Bachert1,3,4. 1. Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University, Ghent, Belgium. 2. Department of Otolaryngology, Supply Base, Saudi Royal Army, Taif, Saudi Arabia. 3. Department of Clinical Science, Intervention and Technology, Division of Ear, Nose and Throat Diseases, Karolinska Institutet, Stockholm, Sweden. 4. Department of Ear, Nose and Throat Diseases, Karolinska University Hospital, Stockholm, Sweden.
Abstract
OBJECTIVES: Nasal polyps are often characterized by type 2 inflammation and disease recurrence. We developed a new surgical technique, referred to as reboot approach, which aims to maximally remove all sinus mucosa and allow healthy re-epithelialization from the preserved nasal mucosa. We here review type 2 endotype chronic rhinosinusitis with nasal polyps (CRSwNP) patients who underwent classical mucosa-sparing endoscopic sinus surgery (ESS) or the reboot approach. METHODS: Retrospective case-control study of 50 consecutive CRSwNP patients who underwent endoscopic sinus surgery between 2015 and 2017, either as a classical non-reboot ESS (n = 20); a partial reboot approach removing the mucosa of the ethmoidal, sphenoidal, and maxillary sinuses (n = 18); or a complete reboot approach including Draf III and removal of all frontal sinus mucosa (n = 12). Polyp recurrence over the follow-up period of 2 years served as the primary outcome. RESULTS: All patients demonstrated a type 2 inflammation of the mucosal tissue harvested during surgery. In the classical approach group (n = 20), nine patients relapsed within 2 years (45%); in the partial reboot group, three out of 18 patients (17%) relapsed; and in the full reboot group one out of 12 patients (8%) relapsed. The relapse rates were significantly different between the non-reboot and the reboot groups (P = 0.02) but also between all treatment groups (P = 0.038). CONCLUSION: Complete removal of diseased mucosa from the paranasal sinuses (reboot approach) significantly reduces the recurrence of nasal polyps for 30 months postoperatively compared to the current mucosa-sparing approach in type 2 inflammatory CRSwNP. LEVEL OF EVIDENCE: 3b Laryngoscope, 129:1286-1292, 2019.
OBJECTIVES:Nasal polyps are often characterized by type 2 inflammation and disease recurrence. We developed a new surgical technique, referred to as reboot approach, which aims to maximally remove all sinus mucosa and allow healthy re-epithelialization from the preserved nasal mucosa. We here review type 2 endotype chronic rhinosinusitis with nasal polyps (CRSwNP) patients who underwent classical mucosa-sparing endoscopic sinus surgery (ESS) or the reboot approach. METHODS: Retrospective case-control study of 50 consecutive CRSwNP patients who underwent endoscopic sinus surgery between 2015 and 2017, either as a classical non-reboot ESS (n = 20); a partial reboot approach removing the mucosa of the ethmoidal, sphenoidal, and maxillary sinuses (n = 18); or a complete reboot approach including Draf III and removal of all frontal sinus mucosa (n = 12). Polyp recurrence over the follow-up period of 2 years served as the primary outcome. RESULTS: All patients demonstrated a type 2 inflammation of the mucosal tissue harvested during surgery. In the classical approach group (n = 20), nine patients relapsed within 2 years (45%); in the partial reboot group, three out of 18 patients (17%) relapsed; and in the full reboot group one out of 12 patients (8%) relapsed. The relapse rates were significantly different between the non-reboot and the reboot groups (P = 0.02) but also between all treatment groups (P = 0.038). CONCLUSION: Complete removal of diseased mucosa from the paranasal sinuses (reboot approach) significantly reduces the recurrence of nasal polyps for 30 months postoperatively compared to the current mucosa-sparing approach in type 2 inflammatory CRSwNP. LEVEL OF EVIDENCE: 3b Laryngoscope, 129:1286-1292, 2019.
Authors: Atsushi Kato; Anju T Peters; Whitney W Stevens; Robert P Schleimer; Bruce K Tan; Robert C Kern Journal: Allergy Date: 2021-09-15 Impact factor: 14.710
Authors: Alma Aurelia Maniu; Maria Ida Perde-Schrepler; Corina Bianca Tatomir; Mihai Ionuţ Tănase; Maximilian George Dindelegan; Vlad Andrei Budu; Gheorghe Doinel Rădeanu; Marcel Cosgarea; Carmen Aurelia Mogoantă Journal: Rom J Morphol Embryol Date: 2020 Apr-Jun Impact factor: 1.033
Authors: Manuel Berger; Aris I Giotakis; Martin Pillei; Andreas Mehrle; Michael Kraxner; Florian Kral; Wolfgang Recheis; Herbert Riechelmann; Wolfgang Freysinger Journal: Int J Comput Assist Radiol Surg Date: 2021-03-07 Impact factor: 2.924